Skip to main content
Karolinska Development logo

Karolinska Development — Investor Relations & Filings

Ticker · KDEV ISIN · SE0002190926 LEI · 54930011ZA52NKO5W681 ST Financial and insurance activities
Open in API
Filings indexed 761 across all filing types
Latest filing 2013-06-27 Regulatory Filings
Country SE Sweden
Listing ST KDEV

About Karolinska Development

https://www.karolinskadevelopment.com/en

Karolinska Development is an investment company specializing in the life sciences sector. It identifies, finances, and supports the creation and growth of companies developing innovative medical technologies and pharmaceuticals. The firm manages a diversified portfolio of biotechnology and medtech ventures, often originating from academic research, with the goal of developing ground-breaking treatments for severe diseases. Karolinska Development leverages its team's expertise in research, development, and commercialization to guide its portfolio companies, providing both capital and strategic support to advance innovations toward the market.

Recent filings

Filing Released Lang Actions
Karolinska Development inleder samarbete med Ospedale San Raffaele och Medicinska universitetet i Graz
Regulatory Filings Classification · 1% confidence The document is a press release dated June 27, 2013, announcing that Karolinska Development has signed 'deal flow agreements' with two major research institutions (Ospedale San Raffaele and Medical University of Graz) to gain access to life science projects for investment. This announcement details strategic business development and partnership activities, which falls under general corporate news or strategic updates. It is not a formal regulatory filing like a 10-K, an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). Since it announces a strategic business development/partnership, it is best classified as a general Regulatory Filing (RNS) as it is a public announcement that may be subject to disclosure rules, or potentially a general Corporate Information filing if one existed. Given the provided options, RNS serves as the best general regulatory announcement/press release category for significant, non-standard corporate news that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP). The content is a strategic business update, not a financial report or a management change.
2013-06-27 Swedish
Karolinska Development invests in Forendo Pharma
M&A Activity Classification · 1% confidence The document announces a specific investment by Karolinska Development AB into Forendo Pharma Oy, detailing the amount invested (EUR 1.2m initially, expected total EUR 3.0m commitment), the ownership stake (21%), and the nature of the investment (drug development programs). This clearly falls under activities related to company financing, fundraising, or capital structure changes, as it involves deploying capital into another entity for development purposes. This aligns best with the 'Capital/Financing Update' category (CAP). It is not an earnings release (ER), an annual report (10-K), or a general regulatory filing (RNS), as it concerns a specific corporate finance action.
2013-06-25 English
Karolinska Development investerar i Forendo Pharma
M&A Activity Classification · 1% confidence The document is a press release dated June 25, 2013, announcing that Karolinska Development AB, along with partners, has invested in a Finnish pharmaceutical development company, Forendo Pharma Oy. The text details the investment amount (€3.0 million from Karolinska Development), the ownership stake (21%), and the development pipeline (endometriosis treatment and fispemifene for low testosterone). This type of announcement, detailing a specific investment, financing round, or capital structure change involving another entity, aligns best with the 'Capital/Financing Update' category. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), but a specific corporate action related to capital deployment.
2013-06-25 Swedish
Athera and Boehringer Ingelheim enter into an option agreement on a novel therapy for Atherosclerosis
M&A Activity Classification · 1% confidence The document announces a significant business event: an option agreement between Athera Biotechnologies AB and Boehringer Ingelheim regarding a novel therapy for Atherosclerosis. This involves granting exclusive rights for future acquisition based on preclinical and Phase I study completion, including an option fee. This type of strategic partnership, licensing, or potential takeover activity falls under Merger & Acquisition (M&A) activity or significant corporate transactions. Given the specific definitions, 'M&A Activity (Code: TAR)' is the most appropriate classification as it relates to proposals or bids that could lead to an acquisition, even if it is structured as an option agreement first. It is not an earnings release (ER), interim report (IR), or a general regulatory filing (RNS), but a specific corporate transaction announcement.
2013-06-19 English
Athera och Boehringer Ingelheim ingår optionsavtal för en innovativ terapi mot åderförkalkning
M&A Activity Classification · 1% confidence The document announces that Athera Biotechnologies has entered into an option agreement with Boehringer Ingelheim for an antibody program related to atherosclerosis. This involves granting an exclusive option to acquire the program following preclinical activities and a Phase I study, in exchange for an option fee. This clearly describes a significant corporate transaction related to financing, asset transfer, or partnership structuring, which falls under 'Capital/Financing Update' (CAP) as it details the terms of a potential future acquisition/licensing deal and associated development funding secured. It is not a standard regulatory report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it details the structure of a deal that secures future funding/value realization, CAP is the most appropriate fit over the general 'RNS' fallback.
2013-06-19 Swedish
EU bidrar med 6 miljoner euro till den kliniska utvecklingen av Atheras antikroppsterapi mot hjärt-kärlsjukdom
Capital/Financing Update Classification · 1% confidence The document is a press release dated June 17, 2013, announcing that Athera Biotechnologies AB has received a research grant of 6 million euros from the EU's Seventh Framework Programme (FP7) to co-finance the clinical development of its antibody therapy PC-mAb. This announcement details a specific corporate event related to funding and development milestones, rather than releasing periodic financial results (ER/IR), announcing management changes (MANG), or reporting insider trades (DIRS). It is a specific announcement concerning financing and development support, which aligns best with the 'Capital/Financing Update' category, although it is specifically about receiving a grant rather than issuing shares or debt. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit for a significant funding announcement that impacts the company's capital structure/development budget. It is not a general regulatory filing (RNS) because it fits a more specific definition.
2013-06-17 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.